The Robert H. Lurie Cancer Center (Lurie Cancer Center) has developed a comprehensive system of protocol review and oversight called the Clinical Protocol Scientific Review and Monitoring System (CPSRMS). This system is comprised of three distinct committees that work collaboratively to provide oversight of all aspects of clinical research conducted at the Lurie Cancer Center. These committees include: the Scientific Review Committee (SRC), the Data Monitoring Committee (DMC), and the Clinical Trial Audit Committee (CTAC). Each committee includes a Chair and/or Co-chair, but the CPSRMS overall is directed by the Associate Director for Clinical Investigations ofthe Lurie Cancer Center, Dr. Al B. Benson. This position is appointed by and reports to Dr. Steven Rosen, the Director ofthe Lurie Cancer Center. The three committees work in conjunction to form a robust system designed to ensure that research conducted at our center has scientific merit and meets the goals and priorities of the center, that clinical trial progress is maintained, and that patient safety and data integrity are maintained for our Northwestern University investigator-initiated trials (NU IITs). The CPSRMS committee responsible for Protocol Review and Monitoring (PRMS) is the SRC. The SRC is charged with the responsibility of evaluating all new and ongoing clinical research protocols for scientific merit, institutional priority and ongoing progress. The committee is a multidisciplinary committee that meets bimonthly to evaluate protocols. All cancer-relevant research studies conducted within the Lurie Cancer Center fall under the purview of this committee and require a level of review. Any faculty member within NU and all Lurie Cancer Center members are required to submit cancer-relevant clinical research protocols to the SRC for review. Protocols are classified into four types: institutional, external peer-reviewed, national/cooperative group, and industrial trials. The different types of protocols undergo different levels of review by the SRC. Any study that is reviewed and approved by an NCI approved peer-review committee (national trials and external peer-reviewed) is exempt from initial and ongoing SRC review for scientific merit. These studies are reviewed administratively for prioritization, and are reviewed annually for progress. All other studies (institutional and industrial) require initial and ongoing SRC review for scientific merit, and also are reviewed for prioritization and progress. Importantly, the NU Institutional Review Board (IRB) requires Lurie Cancer Center endorsement for all cancer-relevant protocols prior to IRB review, therefore ensuring the SRC review requirements have been appropriately met. The administrative support for SRC is coordinated through the Clinical Research Office (CRO).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Gopal, Satish; Achenbach, Chad J; Yanik, Elizabeth L et al. (2014) Moving forward in HIV-associated cancer. J Clin Oncol 32:876-80

Showing the most recent 10 out of 316 publications